AbCellera

Cofounder, CTO, and board member at AbCellera who co-invented the high-throughput microfluidic platform central to its antibody discovery. She previously served as COO from 2019 to 2025 and holds a PhD from the University of British Columbia.

Leads AbCellera's Discovery team, a protein engineer with nearly 15 years of experience in biologics discovery and pre-clinical development. He was previously Senior Director of Biologics Lead Antibody Discovery at Teva.

CFO of AbCellera who helped take the company public on Nasdaq in 2020. He previously spent a decade at STEMCELL Technologies as CFO and Chief Commercial Officer.

VP of Business Development at AbCellera who serves on the boards of LifeSciences BC and Aequus Pharmaceuticals. She previously co-founded Northview Lifesciences and was COO of Aequus Pharmaceuticals.

VP of Quality with nearly 30 years of international biopharmaceutical experience. He was previously Chief Quality Officer for Biocon Biologics and spent 15 years at Genentech/Roche in Basel.

VP of Alliance Management with over 20 years in the biopharmaceutical industry. He previously served as Senior Director of Alliance and Program Management at Halozyme and cofounded Sirenas.

Leads Talent Development at AbCellera. She previously served as Managing Director of Student Development and Services at the University of British Columbia.

Principal of Tower Beach Capital and former CEO of RBC Global Asset Management. He serves on the boards of the Canada Pension Plan Investment Board, Aritzia, and the Asia Pacific Foundation of Canada.

President and CEO of Lyell Immunopharma and former founding CEO of Myovant Sciences. She previously served as CMO of Medivation, leading the clinical development of Xtandi.

Killam Professor of Medical Genetics at UBC and founder of several biotech companies including Xenon, 89bio, and Prilenia. He previously served as CSO and President of Global R&D at Teva.

Leads AbCellera's research, partnership, and license agreements. He previously worked in technology commercialization at Harvard's Office of Technology Development and as a consultant at Lux Research.

Senior leader of the Complex Membrane Protein Technologies team and head of AbCellera's Boston location. He joined via AbCellera's 2020 acquisition of TetraGenetics.

CMO responsible for advancing AbCellera's pipeline programs, a board-certified physician-scientist with over 20 years of drug development experience. She previously held CMO roles at Metagenomi and Maze Therapeutics.

VP of Research Partnerships responsible for managing discovery programs, with over 20 years of biotech management experience and expertise in immunology and single-cell assays.

Professor of Bioengineering and Applied Physics at Stanford and founding co-president of the Chan Zuckerberg Biohub. He has cofounded more than a dozen companies across microfluidics, genomics, and therapeutics.

VP of Communications overseeing executive, corporate, media, and investor relations. She previously co-founded Centrifuge Media Lab and held senior roles in the STEMCELL Group of Companies.

VP of Facilities leading campus development and facilities operations, with over 30 years of experience in health and safety and facilities. She previously directed facilities at QLT and founded MTY Consulting Group.

Legal and compliance executive with over 20 years in biotech and pharma. He was previously a partner at Gibbons P.C. and served as a US Naval Officer.

Pharmaceutical executive with over 20 years of experience, formerly CMO at Array BioPharma. He currently serves on the boards of ADC Therapeutics, Kymera, and Prelude Therapeutics.

Tatiana Solis is a Senior People Partner in People & Culture at AbCellera, based in Vancouver, BC. She previously taught English in South Korea, beginning in 2013, before moving into a people-focused career.